Riskpilot← Back to searchSign inGet full accessITB-MED AB
ABActiveOrg 5590179429Hagaplan 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 201510-19 employees
Revenue 2024
SEK 74,9M
+66% vs 2023
EBITDA margin
3.7%
+13% vs 2023
Equity ratio
51.9%
Financial strength
Net profit 2024
SEK 2,1M
0% vs 2023
| Revenue | SEK 74,9M | +66% |
| EBITDA | SEK 2,8M | +13% |
| Net profit | SEK 2,1M | +0% |
| Total assets | SEK 41,7M | +38% |
| Equity | SEK 21,6M | +10% |
| Employees | — | — |
Legal name
ITB-MED AB
Org number
5590179429
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 juni 2015
Share capital
SEK 1 162 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning och utveckling av immunmodulerande läkemedel, samt därmed förenlig verksamhet.
Address
Hagaplan 4
Email
info@itb-med.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 14 422 | 25 481 | 20 698 | 29 333 | 45 157 | 74 917 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −122 | −3 159 | −30 223 | −104 178 | 854 | 2 691 | 3 465 | 2 488 | 2 808 |
| Depreciation & amort. | −0 | −0 | −3 207 | −498 | −717 | −700 | −782 | −961 | −1 178 |
| EBIT | −122 | −3 159 | −33 430 | −104 676 | 137 | 1 991 | 2 683 | 1 527 | 1 630 |
| Net financials | 58 | −329 | −4 133 | 5 901 | −40 | −9 | 120 | 517 | 416 |
| Profit before tax | −64 | −3 487 | −30 371 | −98 772 | 97 | 1 984 | 2 806 | 2 048 | 2 051 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −64 | −3 487 | −30 371 | −98 772 | 97 | 1 984 | 2 806 | 2 048 | 2 051 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9 947 | 7 088 | 121 384 | 30 331 | 16 293 | 19 351 | 25 596 | 30 149 | 41 669 |
| Equity | 9 937 | 6 449 | 111 418 | 12 645 | 12 742 | 14 726 | 17 532 | 19 580 | 21 631 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 639 | 9 966 | 17 686 | 3 551 | 4 625 | 8 064 | 10 569 | 20 038 |
| Total debt | 10 | 639 | 9 966 | 17 686 | 3 551 | 4 625 | 8 064 | 10 569 | 20 038 |
EBITDA margin
3.7%
This company
15.8%
Market median
-77% vs market
20162024
Equity ratio
51.9%
This company
38.2%
Market median
+36% vs market
20162024
Return on equity
9.5%
This company
18.4%
Market median
-48% vs market
20162024
Net profit margin
2.7%
This company
8.1%
Market median
-67% vs market
20162024
Asset turnover
1.80×
This company
1.12×
Market median
+61% vs market
20162024
Debt / equity
0.93×
This company
0.62×
Market median
+50% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-05-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JD Chief Auditor | Chief Auditor | 2022 | — | — |
KE Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
KD Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
ET Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ZELARION LIMITED | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ZELARION LIMITED
ITB-MED AB (this company)Board members of ITB-MED AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Daniel Åkeborg | Chief Auditor | 0 companies |
| Karl Erik Emanuel Berglund | Chief Executive Officer | 0 companies |
| Karl David Berglund | Chief Executive Officer | 0 companies |
| Eva Therese Kjellberg | Chief Auditor | 0 companies |
| David H Sachs | Board of Directors | 0 companies |
| Pablo Legorreta | Chairman | 0 companies |
| Kasper Emanuel Granlund | Board of Directors | 0 companies |
| Jan Inge Ståhlberg | Deputy Board Member | 0 companies |
| Molly Chiaramonte | Board of Directors | 0 companies |